In addition to providing new insights into the network organization of gip2-stimulated onco-transcriptome in ovarian cancer, the results provide a molecular basis for investigating the therapeutic potential of the hub and bottleneck nodes such as those of UQCRFS1, ACKR3/CXCR7, and FYN for the development of second-line targeted therapy in ovarian cancer. This evidence concerns the gene ACKR3 and ovarian carcinoma.